<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Giant papillary conjunctivitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Giant papillary conjunctivitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Giant papillary conjunctivitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pedram Hamrah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reza Dana, MD, MPH, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). GPC is a noninfectious inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. It is characterized by foreign-body sensation on the upper tarsus, associated with formation of "giant" (&gt;1 mm) papillae. GPC is reviewed here. Other contact lens-related complications are discussed separately. (See  <a class="medical medical_review" href="/d/html/6913.html" rel="external">"Complications of contact lenses"</a>.)</p><p>VKC and AKC are chronic, bilateral, and severe forms of allergic inflammation affecting the ocular surface. These two relatively uncommon types of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly. VKC and AKC are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5549.html" rel="external">"Vernal keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a>.)</p><p>SAC and PAC, the most common forms of ocular allergy, are also discussed separately. (See  <a class="medical medical_review" href="/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p>Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. Toxic conjunctivitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/5555.html" rel="external">"Toxic conjunctivitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>GPC is most commonly associated with wearing of contact lenses and is seen more frequently with soft, hydrogel lenses rather than rigid, gas-permeable (RGP) lenses [<a href="#rid1">1-3</a>]. Approximately 1 to 5 percent of soft contact lens wearers have clinical signs of GPC, and the prevalence is approximately 10-fold less in rigid lens wearers [<a href="#rid1">1</a>]. This difference in prevalence is probably because allergens adhere more readily to the surface of soft contact lenses. Additional factors that influence the incidence of GPC in contact lens wearers include wearing time of contact lenses, cleaning routine (frequency and types of solutions), and duration of contact lens wear [<a href="#rid4">4</a>]. The average onset of GPC after start of contact lens wear is 10 to 20 months for soft contact lenses and 22 to 90 months for rigid lenses [<a href="#rid2">2,3</a>]. However, symptoms may occur as early as three weeks after the start of contact lens wear.</p><p>Other foreign substances that can trigger GPC include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ocular prostheses [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Extruded scleral buckles [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Glaucoma filtering blebs [<a href="#rid7">7</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cyanoacrylate glue [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Band keratopathy [<a href="#rid9">9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Exposed sutures [<a href="#rid10">10</a>]</p><p></p><p>GPC affects predominantly young adults because of the association with contact lenses. There is no sex predilection. A history of atopy is also associated with GPC [<a href="#rid11">11</a>]. The peak distribution of GPC is in the spring and fall, possibly due to increased pollen allergens in the air during this time of the year [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of GPC involves both mechanical and immunologic mechanisms [<a href="#rid13">13</a>]. Debris that can build up on the contact lens surface over time is associated with GPC. This debris may be recognized as foreign to the mucous membranes of the conjunctiva, thereby initiating an immunologic reaction (a combination of type I and type IV hypersensitivity) with repeated antigen presentation. Additionally, trauma from blinking over a foreign substance (such as a contact lens, prosthesis, or suture barb) can provide a port of entry for antigens and induce an immune response.</p><p>The combination of mechanical trauma and immune reaction with release of inflammatory mediators leads to increased lymphocytes, papillary formation, fibroblast proliferation, and collagen production. These factors lead to giant papillae formation.</p><p>The total number of inflammatory cells in the conjunctiva is elevated in GPC [<a href="#rid13">13</a>]. Mast cells, eosinophils, and basophils are increased in biopsies of papillae and are found in both the conjunctival epithelium and the substantia propria [<a href="#rid14">14</a>]. Cells similar to membranous epithelial cells (M cells) in mucosa-associated lymphoid tissue are found in elevated numbers in the conjunctiva of patients with GPC [<a href="#rid15">15</a>]. These cells are involved in the binding, uptake, and translocation of antigens to underlying lymphocytes and antigen-presenting cells.</p><p>Tear levels of immunoglobulin E (IgE) and, in some cases, immunoglobulin M (IgM) and immunoglobulin G (IgG) are elevated in patients with GPC compared with contact lens wearers without GPC and with normal controls. The IgE is produced locally and recognizes the lens material or allergic material contaminants that have adhered to the lens. In addition, levels of leukotriene C4 levels are elevated in tears of GPC patients [<a href="#rid16">16</a>]. Increased numbers of CD4+ T cells and levels of inflammatory cytokines, particularly interleukin (IL) 4, IL-6, soluble IL-6 receptor, and eotaxin, are also seen [<a href="#rid17">17-20</a>].</p><p class="headingAnchor" id="H4"><span class="h1">SIGNS AND SYMPTOMS</span><span class="headingEndMark"> — </span>Symptoms may precede overt signs of GPC and are initially mild at onset. Early symptoms include mild irritation and itching, as well as slight mucus production. If untreated, symptoms gradually progress and may include mucus overproduction (most often noted first thing in the morning), more intense itching, foreign-body sensation, discomfort upon insertion of lenses, blurry vision, and increased awareness of contact lenses [<a href="#rid3">3</a>]. Complete intolerance to wearing contact lenses can develop in severe cases. (See <a class="local">'Diagnosis'</a> below.)</p><p>Signs include enlarged papillae on the upper tarsus, mucus production, conjunctival hyperemia, eyelid thickening, and sometimes ptosis [<a href="#rid3">3</a>]. In the early stages, papillae are rarely larger than 0.3 mm. The papillae often reach 1 to 2 mm in size as the disease progresses (<a class="graphic graphic_picture graphicRef76072" href="/d/graphic/76072.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef74752" href="/d/graphic/74752.html" rel="external">picture 2</a>). Protein deposits of unknown origin are often visible on the contact lens surface. Frequently, signs and symptoms do not perfectly correlate and vary depending on the inciting stimulus. Dryness and blepharitis may exacerbate GPC, as with other allergic conditions affecting the eye. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">HISTOLOGY</span><span class="headingEndMark"> — </span>The typical histology of GPC is thickened and irregular conjunctival epithelium covering giant papillae [<a href="#rid21">21</a>]. Epithelial cells show polymorphism and polymegathism. There are a greater number of conjunctival goblet cells, which appears to be due to the increased conjunctival surface area covering the papillae. GPC is characterized by increased numbers of eosinophils, basophils, mast cells, lymphocytes, and plasma cells in the substantial propria and, to a lesser degree, in the epithelium. The infiltration of these cells demonstrates the immune-mediated features of GPC. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis is made by eliciting a history of contact lens (or prosthesis, suture knot, etc) intolerance and by everting the upper lid and observing enlarged papillae. Both the size and pattern of papillae can vary, as noted previously. (See <a class="local">'Signs and symptoms'</a> above.)</p><p>GPC can be classified into four stages [<a href="#rid2">2</a>], although symptoms and signs do not always correlate, and there is much variation among patients [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In stage I, symptoms include mild mucus discharge after sleeping and mild itching after lens removal. There are no signs or papillae at this stage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In stage II, there is an increase in mucus production and itching, an awareness of the lens, blurred vision, and the development of upper tarsal papillae.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In stage III, there is severe mucus production and itching. The contact lens itself becomes coated with debris. The papillae are increased in number and size. The contact lens may have excessive movement caused by blinking and "grabbing" of the lens by the enlarged papillae. At this stage, there is a reduction in contact lens wearing time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In stage IV, all signs and symptoms are severe, and the contact lenses are worn only briefly.</p><p></p><p>Environmental allergens do not cause GPC, and, therefore, there is no role for testing for environmental allergies.</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes the other types of allergic conjunctivitis and toxic conjunctivitis (see <a class="local">'Introduction'</a> above). The main differentiating feature of GPC is that there is presence of a foreign substance in the eye, such as contact lenses. GPC can be differentiated from seasonal and perennial conjunctivitis in that giant papillae do not form in those types of conjunctivitis. Papillary hypertrophy is seen in vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and occasionally in toxic conjunctivitis. However, it typically occurs in the inferior fornix in patients with AKC, it occurs in a different patient population in patients with VKC (boys living in warm, dry, subtropical climates rather than young adult contact lens wearers), and it is associated with use of ocular medications in patients with toxic conjunctivitis. (See  <a class="medical medical_review" href="/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5549.html" rel="external">"Vernal keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/5555.html" rel="external">"Toxic conjunctivitis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The primary treatment is removal of the source of mechanical irritation. In patients with GPC triggered by contact lenses, improving cleaning and storage of the lenses to prevent protein adherence, reducing the wearing time, increasing the frequency of lens replacement, and changing the type and/or design of the lenses may help. <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> and topical antihistamines, mast cell stabilizers, or dual-acting agents are common adjunctive therapies. Topical corticosteroids are reserved for severe, acute cases. There is no role for allergen immunotherapy since environmental allergens do not cause GPC.</p><p class="bulletIndent1"><span class="glyph">●</span>Contact lens wear should be discontinued for two to four weeks to allow the inflammation to resolve [<a href="#rid3">3,21</a>]. Old contact lenses and storage/cleaning solutions containing preservatives should be thrown out. When possible, the patient should restart contact lens usage with a new pair of lenses. Lens-cleaning agents, along with storing and rinsing solutions, should all be preservative free since hypersensitivity reactions to preservatives can contribute to the inflammatory reaction. However, homemade <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solutions are not advised, due to the risk of bacterial contamination. Daily disinfection with 3% <a class="drug drug_general" data-topicid="113931" href="/d/drug information/113931.html" rel="external">hydrogen peroxide</a> is recommended over other types of disinfection. Enzymatic cleaning of lenses should be performed three times a week or even daily to reduce lens debris [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">Lenses should be replaced at least every three weeks [<a href="#rid23">23</a>]. Changing the type and design of contact lenses may also be beneficial. A switch from extended wear to daily wear (or daily wear to disposable wear) may help to decrease the accumulation of debris and allergens on the contact lens [<a href="#rid24">24,25</a>]. Changing from soft contact lenses to rigid, gas-permeable (RGP) contact lenses may help if other approaches do not succeed.</p><p></p><p class="bulletIndent1">A longer contact lens "holiday" should be initiated if symptoms persist or recur. Lenses can be reintroduced approximately two to three weeks after symptoms resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequent use of preservative-free <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> can provide relief of mild symptoms. (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease", section on 'Artificial tears'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical antihistamines, mast cell stabilizers, and dual-acting agents (eg, <a class="drug drug_general" data-topicid="10177" href="/d/drug information/10177.html" rel="external">olopatadine</a>, <a class="drug drug_general" data-topicid="8798" href="/d/drug information/8798.html" rel="external">azelastine</a> hydrochloride, <a class="drug drug_general" data-topicid="8601" href="/d/drug information/8601.html" rel="external">epinastine</a>, pemirolast potassium, and <a class="drug drug_general" data-topicid="16764" href="/d/drug information/16764.html" rel="external">ketotifen</a> fumarate) can all provide relief of acute itching and reduce eye rubbing by reducing histamine release. <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">Cromolyn</a> sodium has been shown in observational studies to promote resolution of early GPC signs and symptoms when combined with improved lens hygiene [<a href="#rid21">21,26-28</a>]. However, advanced GPC does not respond to cromolyn sodium alone. Olopatadine is the primary treatment of choice among most clinicians, although there are no observational studies or randomized trial of olopatadine in GPC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It may be necessary to use topical "soft" corticosteroids that have a lower risk of causing side effects, such as increased intraocular pressure, than other corticosteroids. <a class="drug drug_general" data-topicid="10116" href="/d/drug information/10116.html" rel="external">Loteprednol</a> etabonate was shown to be effective in improving signs and symptoms of GPC in most patients in several randomized trials [<a href="#rid29">29-32</a>]. Topical corticosteroids should only be used in severe, acute cases of GPC, such as in patients who fail to respond to several weeks of the therapies mentioned previously. In addition, they should be used judiciously and for no longer than four to six weeks. Tapering of corticosteroids is usually done over a two-week period. If the corticosteroid drops have been used for longer than six weeks, they should be tapered more slowly and in correlation with the duration of their usage. Patients on topical corticosteroids should be managed by an ophthalmologist or optometrist because of the risk of side effects.</p><p></p><p class="headingAnchor" id="H2696180483"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Signs and symptoms of GPC usually resolve in less than one week if the source of mechanical irritation is removed. The vast majority of patients who comply with treatment will be able to successfully resume contact lens use.</p><p class="headingAnchor" id="H3259226970"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109230.html" rel="external">"Society guideline links: Allergic eye disease"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Giant papillary conjunctivitis (GPC) is a noninfectious inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. The pathogenesis of GPC involves both mechanical trauma and immune reaction to debris that can build up on the contact lens surface. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– GPC is characterized by foreign-body sensation on the upper tarsus, associated with formation of "giant" (&gt;1 mm) papillae (<a class="graphic graphic_picture graphicRef76072" href="/d/graphic/76072.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef74752" href="/d/graphic/74752.html" rel="external">picture 2</a>). Patients often have intense pruritus and increased mucus production. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis is made by eliciting a history of intolerance of contact lenses or another foreign substance in the eye and by everting the upper lid and observing enlarged papillae. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Signs and symptoms of GPC usually resolve in less than one week if the source of mechanical irritation is removed. In patients with GPC triggered by contact lenses, improving cleaning and storage of the lenses to prevent protein adherence, reducing the wearing time, increasing the frequency of lens replacement, and changing the type and/or design of the lenses may help. The vast majority of patients who comply with treatment will be able to successfully resume contact lens use. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">We suggest a trial of a topical mast cell inhibitor or dual-acting mast cell inhibitor and antihistamine for patients who do not improve with removal of the inciting agent and other nonpharmacologic measures (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We recommend a short course of topical corticosteroids in patients who do not respond to mast cell inhibitors and who have severe disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Binder PS. The physiologic effects of extended wear soft contact lenses. Ophthalmology 1980; 87:745.</a></li><li><a class="nounderline abstract_t">Allansmith MR, Korb DR, Greiner JV, et al. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 1977; 83:697.</a></li><li><a class="nounderline abstract_t">Elhers WH, Donshik PC. Giant papillary conjunctivitis. Curr Opin Allergy Clin Immunol 2008; 8:445.</a></li><li><a class="nounderline abstract_t">Forister JF, Forister EF, Yeung KK, et al. Prevalence of contact lens-related complications: UCLA contact lens study. Eye Contact Lens 2009; 35:176.</a></li><li><a class="nounderline abstract_t">Srinivasan BD, Jakobiec FA, Iwamoto T, DeVoe AG. Giant papillary conjunctivitis with ocular prostheses. Arch Ophthalmol 1979; 97:892.</a></li><li><a class="nounderline abstract_t">Robin JB, Regis-Pacheco LF, May WN, et al. Giant papillary conjunctivitis associated with an extruded scleral buckle. Case report. Arch Ophthalmol 1987; 105:619.</a></li><li><a class="nounderline abstract_t">Vengayil S, Vanathi M, Dada T, et al. Filtering bleb-induced giant papillary conjunctivitis. Cont Lens Anterior Eye 2008; 31:41.</a></li><li><a class="nounderline abstract_t">Carlson AN, Wilhelmus KR. Giant papillary conjunctivitis associated with cyanoacrylate glue. Am J Ophthalmol 1987; 104:437.</a></li><li><a class="nounderline abstract_t">Heidemann DG, Dunn SP, Siegal MJ. Unusual causes of giant papillary conjunctivitis. Cornea 1993; 12:78.</a></li><li><a class="nounderline abstract_t">Sugar A, Meyer RF. Giant papillary conjunctivitis after keratoplasty. Am J Ophthalmol 1981; 91:239.</a></li><li><a class="nounderline abstract_t">Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986; 30:229.</a></li><li><a class="nounderline abstract_t">Begley CG, Riggle A, Tuel JA. Association of giant papillary conjunctivitis with seasonal allergies. Optom Vis Sci 1990; 67:192.</a></li><li><a class="nounderline abstract_t">Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7:429.</a></li><li><a class="nounderline abstract_t">Allansmith MR, Korb DR, Greiner JV. Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology 1978; 85:766.</a></li><li><a class="nounderline abstract_t">Zhong X, Liu H, Pu A, et al. M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis. Arch Immunol Ther Exp (Warsz) 2007; 55:173.</a></li><li><a class="nounderline abstract_t">Irkeç MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm 1999; 7:35.</a></li><li><a class="nounderline abstract_t">Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy 1999; 29:1214.</a></li><li><a class="nounderline abstract_t">Bozkurt B, Akyurek N, Irkec M, et al. Immunohistochemical findings in prosthesis-associated giant papillary conjunctivitis. Clin Exp Ophthalmol 2007; 35:535.</a></li><li><a class="nounderline abstract_t">Shoji J, Inada N, Sawa M. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol 2006; 50:195.</a></li><li><a class="nounderline abstract_t">Moschos MM, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses. Cornea 2004; 23:771.</a></li><li><a class="nounderline abstract_t">Donshik PC, Ballow M, Luistro A, Samartino L. Treatment of contact lens-induced giant papillary conjunctivitis. CLAO J 1984; 10:346.</a></li><li><a class="nounderline abstract_t">Richard NR, Anderson JA, Tasevska ZG, Binder PS. Evaluation of tear protein deposits on contact lenses from patients with and without giant papillary conjunctivitis. CLAO J 1992; 18:143.</a></li><li><a class="nounderline abstract_t">Donshik PC, Porazinski AD. Giant papillary conjunctivitis in frequent-replacement contact lens wearers: a retrospective study. Trans Am Ophthalmol Soc 1999; 97:205.</a></li><li><a class="nounderline abstract_t">Donshik PC. Giant papillary conjunctivitis. Trans Am Ophthalmol Soc 1994; 92:687.</a></li><li><a class="nounderline abstract_t">Hayes VY, Schnider CM, Veys J. An evaluation of 1-day disposable contact lens wear in a population of allergy sufferers. Cont Lens Anterior Eye 2003; 26:85.</a></li><li><a class="nounderline abstract_t">Meisler DM, Berzins UJ, Krachmer JH, Stock EL. Cromolyn treatment of giant papillary conjunctivitis. Arch Ophthalmol 1982; 100:1608.</a></li><li><a class="nounderline abstract_t">Iwasaki W, Kosaka Y, Momose T, Yasuda T. Absorption of topical disodium cromoglycate and its preservatives by soft contact lenses. CLAO J 1988; 14:155.</a></li><li><a class="nounderline abstract_t">Kruger CJ, Ehlers WH, Luistro AE, Donshik PC. Treatment of giant papillary conjunctivitis with cromolyn sodium. CLAO J 1992; 18:46.</a></li><li><a class="nounderline abstract_t">Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 2008; 92:455.</a></li><li><a class="nounderline abstract_t">Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997; 123:455.</a></li><li><a class="nounderline abstract_t">Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997; 23:31.</a></li><li><a class="nounderline abstract_t">Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993; 12:313.</a></li></ol></div><div id="topicVersionRevision">Topic 5553 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6160446" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The physiologic effects of extended wear soft contact lenses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/868969" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Giant papillary conjunctivitis in contact lens wearers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18769199" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474751" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of contact lens-related complications: UCLA contact lens study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/444123" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Giant papillary conjunctivitis with ocular prostheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3619733" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Giant papillary conjunctivitis associated with an extruded scleral buckle. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826299" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Filtering bleb-induced giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3661662" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Giant papillary conjunctivitis associated with cyanoacrylate glue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8458237" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Unusual causes of giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7008616" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Giant papillary conjunctivitis after keratoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082025" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ocular allergy and mast cell stabilizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2320363" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of giant papillary conjunctivitis with seasonal allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873584" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/714378" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557145" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10410873" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469030" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17760635" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunohistochemical findings in prosthesis-associated giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16767372" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502476" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased eotaxin in tears of patients wearing contact lenses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6439429" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of contact lens-induced giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1499118" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of tear protein deposits on contact lenses from patients with and without giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703125" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Giant papillary conjunctivitis in frequent-replacement contact lens wearers: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7886881" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303503" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An evaluation of 1-day disposable contact lens wear in a population of allergy sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6814405" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cromolyn treatment of giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3145159" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Absorption of topical disodium cromoglycate and its preservatives by soft contact lenses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1559288" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of giant papillary conjunctivitis with cromolyn sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245274" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of ocular inflammatory conditions with loteprednol etabonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124242" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9001768" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319490" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
